thought call
wouldnt read anyth weak share today follow strong
result view sell news trend given good ytd
out-performance new fundament concern look guidanc
vast major biopharma peer provid initi outlook
consensu upsid non-gaap ep guidanc midpoint y/i con
big posit revenu side guidanc look conserv
midpoint isnt surpris come cfo paul clanci inde
mani upsid driver includ faster ultomiri convers faster expect
nmo launch barc vs con see quot
prevent nmo kol call continu gmg upsid ou
geographi think alexion right combin differenti growth
cagr revenu ep peer plu
expand pipelin meaning near-term clinic progress evid includ
ultomiri ahu waiha gmg wilson diseas
unlik investor less concern competit threat core
complement franchis given alexion commerci lead new product cycl
ultomiri persuas patient physician compar mani
unproven clinic stage option given attract growth potenti expand
pipelin alexion remain top pick reiter overweight pt
pipelin updat ultomiri ahu us submiss remain track
follow eu japan gmg phase schedul start follow
nmosd plan poc studi al ppm also way phase
ultomiri sq formul initi outsid complement
anti-fcrn waiha gmg pivot trial also like start
model adjust follow call forecast revenu
respect similarli adjust
non-gaap ep estim respect
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
growth soliri pnh/ahu growth driven
sale refractori gmg assum
approv extend dose option
pnh ahu support long-term
viabil complement franchis recent fx
improv
greater expect growth soliri current
indic ahu pnh gmg label
expans soliri nmo posit data
rapid uptak iv
subcutan formul support upsid case
biosimilar competit soliri
time frame high price pressur ww
geographi addit failur
pnh ahu increas fx headwind
macroeconom issu support downsid case
except per op analysisoldnewoldnewr barclay
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
